As per the study published in British medical journal Lancet, researchers analysed patients' response to the first off-label use of two antiviral medications - brincidofovir and tecovirimat - developed to treat smallpox. It found little evidence that brincidofovir was of clinical benefit but concluded that further research into the potential of tecovirimat would be warranted.from Industry-Economic Times
Read The Rest:economictimes...
